There were 135 press releases posted in the last 24 hours and 170,189 in the last 365 days.

U.S Secondary Hyperparathyroidism Treatment (SHPT) Market Size Worth USD 7.06 Billion by 2026; Increasing Launch of Effective Drugs Will Create Growth Opportunities

Key Companies Covered in U.S Secondary Hyperparathyroidism Treatment (SHPT) Market report are Amgen Inc., Teva Pharmaceutical Industries Ltd., Genzyme Corporation (Sanofi), AbbVie Inc., Cipla Inc., Dr. Reddy’s Laboratories Ltd., OPKO Health, Inc. & Other Prominent Players

/EIN News/ -- Pune, Nov. 18, 2019 (GLOBE NEWSWIRE) -- The increasing launch of effective drugs is a key factor driving the U.S. secondary hyperparathyroidism treatment market, says Fortune Business Insights in a report, titled “U.S Secondary Hyperparathyroidism Treatment (SHPT) Market Size, Share & Industry Analysis, By Drug Class (Calcimimetics, Vitamin D Analogues, and Phosphate Binders), By Distribution Channel (Hospital & Retail Pharmacies, Online Channels, and Others) and Region Forecast, 2019-2026.” The secondary hyperparathyroidism treatment (SHPT) market was valued at USD 4.34 Billion in 2018 and is expected to reach USD 7.06 Billion by 2026, exhibiting a CAGR of 9.0%.

As per the report the secondary hyperparathyroidism treatment market on the basis of drug class is segmented into calcimimetics, vitamin d analogues, and phosphate binders. The calcimimetics segment is expected to hold maximum share during the forecast period owing to the numerous generic substitutes of Cinacalcet in the U.S. along with the rising demand for potent and specific therapy for the treatment of SHPT. For instance, according to a national survey conducted by American Journal of Kidney Diseases the use of Cinacalcet has increased from 23% to 31% between 2014 and 2017

The report provides a comprehensive assessment of the U.S SHPT market by inculcating valuable insights, facts, industry-related information, and historical data. Numerous approaches and methods are implemented to make meaningful assumptions and views. Furthermore, it offers a detailed analysis and information as per market segments, helping readers to get an inclusive overview of the market.


Browse Detailed Summary of 114 Pages Premium Report Enabled with Major Segmentation, Top Players Profile, Regional Analysis and Forecast Details: https://www.fortunebusinessinsights.com/industry-reports/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664


List of Prominent Companies present in U.S Secondary Hyperparathyroidism Treatment (SHPT) Market report includes;

  • Amgen Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Genzyme Corporation (Sanofi)
  • AbbVie Inc.
  • Cipla Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • OPKO Health, Inc.
  • Other Prominent Players

Emerging Guidelines By Government Authorities Will Boost Growth

The increasing government initiatives for improvising secondary hyperparathyroidism management will create growth opportunities for the secondary hyperparathyroidism treatment market. The aim of SHPT treatment is to manage the biochemical markers of bone and mineral metabolism, which are directly linked to cardiovascular events and bone fractures by extensive epidemiologic evidence. International & national organizations in the U.S. and working groups such as the National Kidney Foundation have published various clinical guidance documents to encourage best practices in managing SHPT.


Get Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-secondary-hyperparathyroidism-shpt-treatment-market-101664


Furthermore, increasing awareness about SHPT in physicians, as well as clinical specialists, have improved the treatment regimen for its management. The improvement in earlier identification and assessment of SHPT for mineral metabolism in CKD & ESRD will have a positive impact on secondary hyperparathyroidism treatment market growth. The reduction in associated complications for the management of SHPT is expected to accelerate growth of the market during the forecast period.

Rising Prevalence Of Chronic Kidney Disease Will Stimulate Growth

The increasing prevalence of chronic kidney disease among geriatric population as well as general population will enable the growth of the secondary hyperparathyroidism treatment market during the forecast period. According to the Centers for Disease Control and Prevention (CDC), around 15% of U.S adults, which, is, 37 million people are estimated to have chronic kidney disease. Additionally, CKD is found more common in people aged 65 years or older than in people aged 45-64 years. The rising cases of renal disease and increasing patient pool will have a significant impact on the market. 

The increasing cost burden for the treatment of secondary hyperparathyroidism will further encourage growth of the market. In addition, the launch of generic form of Cinacalcet hydrochloride tablets will bode well for the secondary hyperparathyroidism treatment market. For instance, Cipla Inc. and its subsidiary Cipla USA Inc. announced the launch of a generic form of Cinacalcet hydrochloride tablets in USA. Moreover, Amgen Inc. announced the USFDA approval of Parsabiv for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD). The approval for Parsabiv will also aid the growth of the market during the forecast period.


Detailed Table of Content:

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Prevalence of Secondary Hyperparathyroidism, 2018
    • Distribution of Secondary Hyperparathyroidism Patients by Treatment Type – Surgery, Drugs   and Others, 2018
    • Key Industry Developments – Mergers, Acquisitions and Partnerships
    • Pipeline Analysis
    • Reimbursement Scenario
    • Cost Burden of Secondary Hyperparathyroidism
  • U.S. Secondary Hyperparathyroidism Treatment Market Analysis, Insights, and Forecast, 2015-2026
    • Market Analysis, Insights, and Forecast – By Drug Class
      • Calcimimetics
      • Vitamin D Analogues
      • Phosphate Binders
    • Market Analysis, Insights, and Forecast – By Distribution Channel
      • Hospital & Retail Pharmacies
      • Online Pharmacies
      • Others
    • Market Analysis, Insights, and Forecast – By Region
      • West
      • Midwest
      • South
      • Northeast

TOC Continued...!


Order a Single or Multi-User License Copy: https://www.fortunebusinessinsights.com/checkout-page/101664


Have a Look at Related Reports:
Antipsychotic Drugs Market Size, Share and Industry Analysis, By Disease (Schizophrenia, Bipolar Disorder, Unipolar Depression, Dementia, Others), By Therapeutic Class (First Generation, Second Generation, Third Generation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019 – 2026

Autism Spectrum Disorder Therapeutics Market Size, Share and Global Trend By Type (Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, Others), By Treatment Type (Communication & Behavioral Therapies, Drug Therapies) and Geography Forecast till 2026

Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Treatment Market Size, Share and Global Trend By Infection Type (Hospital-acquired ABSSSI, Community-acquired ABSSSI), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026


About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com

Primary Logo


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.